Low Dose Oral Minoxidil in COVID-19-Associated Telogen Effluvium: A Retrospective Analysis of 69 Patients

This study suggests that low-dose oral minoxidil is safe and effective in treating COVID-19 associated telogen effluvium, as indicated by a significant decrease in hair-shedding scores over follow-up visits.

Oral minoxidil significantly reduces hair shedding in women with chronic telogen effluvium.

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

In this study of 36 women with chronic telogen effluvium, once daily oral minoxidil significantly reduced hair shedding over 12 months, though some participants experienced facial hypertrichosis and other mild side effects. The authors concluded that placebo-controlled studies are needed to confirm these results.

This abstract reviews the use of low dose oral minoxidil as a monotherapy for hair loss and reports no new clinical data.